These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J. Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [Abstract] [Full Text] [Related]
10. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):e135-42. PubMed ID: 21345617 [Abstract] [Full Text] [Related]
16. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer. Liauw SL, Liauw SH. Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):751-7. PubMed ID: 20932666 [Abstract] [Full Text] [Related]
18. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL. Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):235-41. PubMed ID: 21163587 [Abstract] [Full Text] [Related]
19. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535 [Abstract] [Full Text] [Related]
20. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Martínez-Monge R, Moreno M, Ciérvide R, Cambeiro M, Pérez-Gracia JL, Gil-Bazo I, Gaztañaga M, Arbea L, Pascual I, Aristu J. Int J Radiat Oncol Biol Phys; 2012 Mar 01; 82(3):e469-76. PubMed ID: 22284039 [Abstract] [Full Text] [Related] Page: [Next] [New Search]